Report

The OS-PCORTF Annual Report provides project descriptions for each of the OS-PCORTF portfolio’s 25 projects that were active in calendar 2018.

The OS-PCORTF Annual Report provides project descriptions for each of the OS-PCORTF portfolio’s 27 projects that were active in calendar year 2019, as well as the major accomplishments.

The OS-PCORTF Annual Report provides project descriptions for each of the OS-PCORTF portfolio’s 34 projects that were active in calendar year 2020, as well as the major accomplishments.

This Annual Evaluation Plan is one of several required Evidence Act products, including the 4-year Evidence-Building Plan (also referred to as the Learning Agenda), Capacity Assessment, and agency Evaluation Policy. The FY2023 Evaluation Plan priority areas are aligned with the goals of the FY 2022-2026 HHS Strategic Plan and the FY 2023- 2026 HHS Evidence-Building Plan.

Under the Foundations for Evidence-Based Policymaking Act of 2018 (Evidence Act), the Capacity Assessment requires agencies to assess the coverage, quality, methods, effectiveness, and independence of their statistics, evaluation, research, and analysis efforts.

The HHS Evidence Building Plan, required by the Evidence Act, is a systematic plan for identifying and addressing policy questions relevant to the programs, policies, and regulations of the agency.

The rapid emergence of the novel Coronavirus Disease 2019 (COVID-19) pandemic spurred national concerns about the social determinants of health (SDOH) as risk factors for infection and their potential to negatively impact health outcomes.

Many human services programs recognize the power of “social capital,” or the value that arises from relationships. This report offers insight into how programs use peer supports to help build social capital with participants who are reentering the community after incarceration or are survivors of intimate partner violence or sex trafficking.

The Centers for Medicare & Medicaid Services (CMS) has recently given new flexibilities to Medicare Advantage (MA) plans to provide supplemental benefits that address long-term services and supports (LTSS) needs and social determinants of health (SDOH) among their members.

The purpose of this study was to estimate the cost of generic drug development and approval. This study develops an analytical framework for examining the expected net present value (ENPV) (i.e., the difference between the present value of expected revenues over product life and cost of product development and approval) to a generic drug developer in different size drug markets.